Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: Where do we stand?

British Journal of Ophthalmology

Volumn 94, Issue 2, 2010, Pages 143-145

  Kaiser, Peter K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GLUCOSE; PEGAPTANIB; PLACEBO; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VERTEPORFIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EDITORIAL; FOLLOW UP; HUMAN; INCIDENCE; PATHOGENESIS; PATIENT COMPLIANCE; PERICYTE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN SECRETION; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; UPREGULATION; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76149137247     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.159863     Document Type: Editorial

References (14)

1. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:7-21.
2. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis 2003;9:747-55.
3. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
4. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
5. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007;10:141- 8.
6. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-53.
7. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
8. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-57.
9. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-41.
10. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.
11. Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2009;94:180-4.
12. Meyer C, Eter N, Holz F, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: interim results from the SUSTAIN trial. Invest Ophthalmol Vis Sci 2008;49:e-abstract 273.
13. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
14. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study. Br J Ophthalmol 2009;94:174-9.